CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Clopidogrel 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01815008
NCT01815008Phase 4Completed
CompareCT.gov

PHARMACOGENOMICS OF ANTI-PLATELET RESPONSE - I

Johns Hopkins University·interventional·Posted Mar 20, 2013·Updated Jan 9, 2017

In Brief

A Phase 4 clinical trial evaluating Clopidogrel and Aspirin for Platelet Aggregation and 2 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This clinical trial is examining the role of genetic polymorphism on the effect of clopidogrel (with or without aspirin) on platelet response in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatelet Aggregation, Platelet Transcriptome, Coronary Artery Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 20, 2013
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.3 years ago

Interventions

Clopidogreldrug

Clopidogrel 75 mg daily

Aspirindrug

Aspirin 81 mg daily